Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy

Akira Kabashima, Dai Kitagawa, Toshihiko Nakamura, Naoko Kondo, Seiichi Teramoto, Genkichi Saito, Tomoru Funahashi, Eisuke Adachi, Yoichi Ikeda

Research output: Contribution to journalArticle

Abstract

A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.

Original languageEnglish
Pages (from-to)1716-1718
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume41
Issue number12
Publication statusPublished - Nov 1 2014

Fingerprint

oxaliplatin
Rectal Neoplasms
Costs and Cost Analysis
Recurrence
Drug Therapy
Colostomy
Leucovorin
Fluorouracil
Colonic Neoplasms
Walking
Cicatrix
Quality of Life
Biopsy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kabashima, A., Kitagawa, D., Nakamura, T., Kondo, N., Teramoto, S., Saito, G., ... Ikeda, Y. (2014). Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy. Gan to kagaku ryoho. Cancer & chemotherapy, 41(12), 1716-1718.

Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy. / Kabashima, Akira; Kitagawa, Dai; Nakamura, Toshihiko; Kondo, Naoko; Teramoto, Seiichi; Saito, Genkichi; Funahashi, Tomoru; Adachi, Eisuke; Ikeda, Yoichi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 41, No. 12, 01.11.2014, p. 1716-1718.

Research output: Contribution to journalArticle

Kabashima, A, Kitagawa, D, Nakamura, T, Kondo, N, Teramoto, S, Saito, G, Funahashi, T, Adachi, E & Ikeda, Y 2014, 'Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 41, no. 12, pp. 1716-1718.
Kabashima A, Kitagawa D, Nakamura T, Kondo N, Teramoto S, Saito G et al. Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy. Gan to kagaku ryoho. Cancer & chemotherapy. 2014 Nov 1;41(12):1716-1718.
Kabashima, Akira ; Kitagawa, Dai ; Nakamura, Toshihiko ; Kondo, Naoko ; Teramoto, Seiichi ; Saito, Genkichi ; Funahashi, Tomoru ; Adachi, Eisuke ; Ikeda, Yoichi. / Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2014 ; Vol. 41, No. 12. pp. 1716-1718.
@article{22a81f6fafa645c3a74f925de43ab52a,
title = "Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy",
abstract = "A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.",
author = "Akira Kabashima and Dai Kitagawa and Toshihiko Nakamura and Naoko Kondo and Seiichi Teramoto and Genkichi Saito and Tomoru Funahashi and Eisuke Adachi and Yoichi Ikeda",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "41",
pages = "1716--1718",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy

AU - Kabashima, Akira

AU - Kitagawa, Dai

AU - Nakamura, Toshihiko

AU - Kondo, Naoko

AU - Teramoto, Seiichi

AU - Saito, Genkichi

AU - Funahashi, Tomoru

AU - Adachi, Eisuke

AU - Ikeda, Yoichi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.

AB - A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.

UR - http://www.scopus.com/inward/record.url?scp=84928416815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928416815&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1716

EP - 1718

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -